glp 1 agonist drugs side effects A monthly GLP-1 dose could cut the number of shots patients take each year from 52 to 12. from the drug — mainly gastrointestinal symptoms — were similar to or Updated Ranking and Side Effects

95% CI 0.79 0.99

Curiously, LEADER revealed a downward trend in hospitalization rates for heart failure (-13%, P = 0.14) [4]

Wegovy vision loss lawsuits can now be filed or transferred to IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (MDL Number 3163)

The half-life of oral semaglutide is approximately 1 week, aligning with subcutaneously administered form (102)

It has multiple actions including: potentiation of glucose-mediated insulin secretion mechanisms identified: increased -cell proliferation, resulting in an increase -cell mass (Fusco et al, 2017) stimulation of insulin biosynthesis at the translational level, helping to maintain -cell insulin stores and secretory capacity (Baggio & Drucker, 2007) because the GLP-1 effect is glucose-dependent (there is more insulin release when glucose levels are elevated, but less effect when glucose levels are normal), GLP-1 agonists have a lower risk for producing hypoglycemia compared to sulfonylureas (that chronically stimulate insulin release, independent of glucose concentration) suppression of postprandial glucagon release Evidence indicates that stimulation of pancreatic cells by GLP-1 increases their glucose sensitivity, resulting in less glucagon release at any glucose level (Baggio & Drucker, 2007)